Keyword: MedImmune Ventures
Pandion Therapeutics is working on localized treatments for autoimmune and inflammatory disease.
After a failed trial in May, AstraZeneca hoped tralokinumab could pass subpopulation tests and make it to the finish line, but it wasn’t meant to be.
AstraZeneca and MedImmune have hired a clutch of new cancer R&D execs.
AstraZeneca’s biologics arm MedImmune and synthetic biology co Abpro have joined forces on a new Ang2-VEGF research collab that will come together under a new spinout.